Institutional Investors Position Themselves for Bitcoin Surge After Recent Price Dip

US
Published:

In a significant turn of events, large institutional investors have reportedly accumulated over 34,000 Bitcoin (BTC), amounting to approximately $3.2 billion, following a notable price dip in December 2024. This buying spree comes after a peak price of over $108,000 was reached on December 17, leading to a sell-off of around 79,000 BTC, driven predominantly by wallets holding between 1,000 and 10,000 BTC.

Market analyst Cauê Oliveira from Blocktrends noted that these large investors seized the opportunity to buy Bitcoin at lower prices, specifically under $95,000, using a strategy involving smaller, multiple trades. This accumulation contributes to a partial recovery in Bitcoin’s value, which is currently trading around $94,900—reflecting a minor decline of 2.3% influenced by broader market conditions.

Optimism remains strong among analysts regarding Bitcoin's potential. Fidelity Digital Assets' Matt Hogan has suggested that increased interest from nation-states, central banks, and sovereign wealth funds is likely, asserting that upcoming pro-crypto policies under the incoming US president could further enhance Bitcoin's attractiveness.

Additionally, Bitfinex analysts highlighted a rapid decrease in Bitcoin's market liquidity, pointing to the possibility that the worst of the recent downward pressures may have subsided. Projections indicate that in a worst-case scenario, Bitcoin could exceed $150,000, with optimistic assessments suggesting a rise to over $400,000.

Despite the recent market volatility, the actions of institutional investors signal a robust confidence in Bitcoin's future, potentially setting the stage for a significant price rally in 2025.

Weekly Newsletter

News summary by melangenews

Loading...

More from United States

Tragic Collision of Passenger Plane and Military Helicopter in Washington Claims 67 Lives

A catastrophic midair collision between a passenger plane and a military helicopter in Washington D.C. on Wednesday resulted in the deaths of all 67 individuals on board. The incident involved American Airlines flight 5342, which was a Bombardier CRJ-700 carrying 60 passengers and four crew members, and a military Sikorsky H-60 Black Hawk helicopter occupied by three service members. The collision occurred over the Potomac River at approximately 8:48 PM local time while the plane was making its final approach to Ronald Reagan Airport. Eyewitness reports indicated that the helicopter veered dangerously close to the aircraft before the impact, causing both to explode in midair. Emergency teams recovered 28 bodies from the plane and one from the helicopter, confirming that no survivors emerged from the wreckage. American Airlines expressed its condolences and stated that it is cooperating with investigation efforts, while President Donald Trump commented on the tragedy, stating it "seemed avoidable" given the clear weather conditions and routine approach procedure. A joint investigation by civil and military authorities is underway to determine the accident's cause.
US

FDA Approves Revolutionary Bioengineered Blood Vessel for Trauma Treatments

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking bioengineered blood vessel aimed at addressing the needs of trauma patients. Developed by North Carolina-based Humacyte, this vessel is designed to integrate with a patient’s body over time, providing a solution for individuals who have suffered severe injuries that impede blood circulation, particularly in cases of amputation. According to founder and CEO Laura Niklason, traditional treatments using veins are often inadequate, especially when patients cannot provide usable options from their own bodies. The FDA approval follows extensive testing involving 51 civilian and 16 military patients, revealing that nearly 92% of the engineered vessels remained functional after 30 days, compared to 79% for synthetic alternatives. Additionally, the infection rate for the bioengineered vessels was under 1%, significantly lower than the over 8% rate associated with synthetic grafts, as published in the journal JAMA Surgery. While the approved application is limited to trauma cases, Humacyte is exploring additional uses for its technology, including potential applications in kidney dialysis and peripheral artery disease.
US

Trump Plans to Detain 30,000 Migrants at Guantanamo Bay

Former President Donald Trump has outlined a controversial plan to detain up to 30,000 migrants at the Guantanamo Bay detention facility if he is re-elected in 2024. According to a statement released by Trump's campaign, this measure aims to address illegal immigration and bolster national security. This proposal comes amidst intensifying discussions on immigration policies in the United States, reflecting Trump's previously embraced hardline stance during his presidency. Trump's administration was marked by strict immigration measures, including family separations and the construction of barriers along the U.S.-Mexico border. Critics of the plan have raised concerns about humanitarian implications and the legality of detaining a large number of migrants indefinitely. Legal experts argue that such actions could face significant pushback in courts. The proposal reflects a broader trend among certain political leaders advocating for stringent immigration control as a response to increasing cross-border migration. As the 2024 presidential election approaches, Trump's immigration policy is expected to be a focal point of debate among candidates.
US